# APC

Source: https://onco.cc/targets/apc/  
OnCo record `apc` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

APC (Adenomatous polyposis coli protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Hepatocellular carcinoma and 5 more.

## Summary

Tumour suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signalling as a negative regulator. APC activity is correlated with its phosphorylation state.

CIViC holds 5 clinical evidence items and 0 assertions across 2 variants, naming JW55, G007-LK, Nirogacestat and Regorafenib. Open Targets scores its association with cancer at 0.91 (direct and indirect evidence; datatypes genetic literature 0.79, affected pathway 0.86, literature 1.00, genetic association 0.90, somatic mutation 0.97, animal model 0.88). IntOGen calls it a driver in 43 cohorts (2 activating, 41 loss-of-function), covering Acute Myeloid Leukaemia, Anal Squamous Cell Carcinoma, Cholangiocarcinoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Cutaneous Squamous Cell Carcinoma and others. In OnCo, 1 product record names it (Nirogacestat).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: APC regulator of Wnt signaling pathway; Adenomatous polyposis coli protein; DP2; DP3; DP2.5; PPP1R46
- Tags: cancer-genes-wave
- Symbol: APC
- Class: tumor-suppressor
- Biology: Tumour suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signalling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)-induced cell migration. Required for MMP9 up-regulation via the JNK signalling pathway in colorectal tumour cells. Location: Cell junction, adherens junction; Cytoplasm, cytoskeleton; Cell projection, lamellipodium; Cell projection, ruffle membrane (UniProt). Locus 5q22.2 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.86 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease; Gastric & gastro-oesophageal junction cancer: Open Targets association 0.81 with gastric cancer (MONDO_0001056); IntOGen driver in 6 cohorts (EGC, STAD, STOMACH); Hepatocellular carcinoma: Open Targets association 0.74 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 2 cohorts (HCC); Prostate cancer: Open Targets association 0.65 with prostate cancer (MONDO_0008315); IntOGen driver in 7 cohorts (PRAD, PROSTATE); Oesophageal cancer: Open Targets association 0.55 with oesophageal cancer (MONDO_0007576); IntOGen driver in 4 cohorts (ESCA, ESCC); Biliary tract cancer: Open Targets association 0.58 with biliary tract cancer (MONDO_0003060)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 41 cohorts; CIViC holds 5 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:583: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:583
- UniProt P25054: https://www.uniprot.org/uniprotkb/P25054/entry
- NCBI Gene 324: https://www.ncbi.nlm.nih.gov/gene/324
- Ensembl ENSG00000134982: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134982

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Anal cancer (squamous cell carcinoma)](https://onco.cc/cancers/anal/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Nirogacestat](https://onco.cc/drugs/nirogacestat/)
- pathways: [Colorectal cancer (KEGG map)](https://onco.cc/pathways/colorectal-cancer-signalling/), [Gastric cancer (KEGG map)](https://onco.cc/pathways/gastric-cancer-signalling/), [Mitosis & the spindle assembly checkpoint](https://onco.cc/pathways/mitotic-spindle-checkpoint/), [Wnt / β-catenin](https://onco.cc/pathways/wnt/)

---
JSON: https://onco.cc/api/v1/entities/apc.json